Comparative Efficacy of Chimeric Porcine Circovirus (PCV) Vaccines against Experimental Heterologous PCV2d Challenges

The objective of this study was to evaluate the efficacy of two multivalent commercial porcine circovirus (PCV) vaccines against heterologous PCV2d challenges. A total of 24 crossbred male pigs aged 26 days selected from a specific pathogen-free herd were randomly divided into four groups (six pigs...

Full description

Saved in:
Bibliographic Details
Published inVeterinary sciences Vol. 10; no. 2; p. 80
Main Authors Wongchanapai, Pichanun, Yamsakul, Panuwat, Arunorat, Jirapat, Guntawang, Thunyamas, Sittisak, Tidaratt, Srivorakul, Saralee, Photichai, Kornravee, Thanawongnuwech, Roongroje, Sukmak, Manakorn, Pringproa, Kidsadagon
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 21.01.2023
MDPI
Subjects
Analysis
Antibodies
Antigens
blood
challenge
chimeric vaccine
Genotypes
herds
heterologous PCV2
Histopathology
Hogs
Immune response
Immunization
Immunoglobulin G
Immunology
Infectious diseases
Inoculation
Laboratory animals
Lungs
Lymphatic system
males
Pathogens
Porcine circovirus
Porcine circovirus type 2
Specific pathogen free
specific pathogen-free animals
Swine
Vaccination
Vaccines
Variance analysis
Viremia
Thailand
United States > US
challenge
Porcine circovirus type 2
heterologous PCV2
chimeric vaccine
Online AccessGet full text

Cover

Abstract The objective of this study was to evaluate the efficacy of two multivalent commercial porcine circovirus (PCV) vaccines against heterologous PCV2d challenges. A total of 24 crossbred male pigs aged 26 days selected from a specific pathogen-free herd were randomly divided into four groups (six pigs per group) and assigned as follows: negative control (unvaccinated/sham-challenge), vaccinated with chimeric PCV1-2a vaccine (PCV1-2a/PCV2d-challenge), vaccinated with chimeric PCV1-2a-2b vaccine (PCV1-2a-2b/PCV2d-challenge) and positive control (unvaccinated/PCV2d-challenge). At 21 days after vaccination, the pigs were intranasally and intramuscularly inoculated with either sham or field isolates of PCV2d (PCV2d/149/TH/2020). After being challenged, blood samples were obtained weekly and analyzed for levels of PCV2d viremia, neutralizing antibodies, and IgG against PCV2. At 30 days post-challenge (DPC), the pigs were euthanized and then subjected to pathological evaluations and molecular analysis. The results indicated that pigs in the PCV1-2a-2b/PCV2d-challenge and the PCV1-2a/PCV2d-challenge groups possessed significantly greater levels of PCV2d-neutralizing antibody titer when compared with the positive control group. Moreover, pigs in the PCV1-2a-2b/PCV2d-challenge group exhibited a lower degree of severity in terms of gross lesion scores and lower levels of PCV2 viremia when compared with the positive control group. This study demonstrated that vaccinating pigs with either the PCV1-2a or PCV1-2a-2b chimeric vaccines elicits a potent immune response against PCV2d infection and reduces viremia after PCV2d inoculation in pigs.
AbstractList The objective of this study was to evaluate the efficacy of two multivalent commercial porcine circovirus (PCV) vaccines against heterologous PCV2d challenges. A total of 24 crossbred male pigs aged 26 days selected from a specific pathogen-free herd were randomly divided into four groups (six pigs per group) and assigned as follows: negative control (unvaccinated/sham-challenge), vaccinated with chimeric PCV1-2a vaccine (PCV1-2a/PCV2d-challenge), vaccinated with chimeric PCV1-2a-2b vaccine (PCV1-2a-2b/PCV2d-challenge) and positive control (unvaccinated/PCV2d-challenge). At 21 days after vaccination, the pigs were intranasally and intramuscularly inoculated with either sham or field isolates of PCV2d (PCV2d/149/TH/2020). After being challenged, blood samples were obtained weekly and analyzed for levels of PCV2d viremia, neutralizing antibodies, and IgG against PCV2. At 30 days post-challenge (DPC), the pigs were euthanized and then subjected to pathological evaluations and molecular analysis. The results indicated that pigs in the PCV1-2a-2b/PCV2d-challenge and the PCV1-2a/PCV2d-challenge groups possessed significantly greater levels of PCV2d-neutralizing antibody titer when compared with the positive control group. Moreover, pigs in the PCV1-2a-2b/PCV2d-challenge group exhibited a lower degree of severity in terms of gross lesion scores and lower levels of PCV2 viremia when compared with the positive control group. This study demonstrated that vaccinating pigs with either the PCV1-2a or PCV1-2a-2b chimeric vaccines elicits a potent immune response against PCV2d infection and reduces viremia after PCV2d inoculation in pigs.
Disease caused by infection with porcine circovirus type 2 (PCV2), collectively known as porcine circovirus-associated disease (PCVAD), is one of the most important viral infectious diseases in pigs. To date, PCV2 has been classified into at least 8 genotypes, namely PCV2a, PCV2b, PCV2c, PCV2d, PCV2e, PCV2f, PCV2g, and PCV2h. Among these, PCV2a, PCV2b, and PCV2d are the predominant genotypes that have chronologically circulated and affected the global pig population. Application of the PCV2 vaccine is a key strategy in the prevention and control of PCV2 infection. However, to the best of our knowledge, little is known about the benefits of using the chimeric PCV2a-2b antigen-based vaccine in Thailand in experimental challenges with field isolates of PCV2d. The present study has demonstrated that the chimeric PCV1-2a-based vaccine and the chimeric PCV1-2a-2b-based vaccine are effective against Thai PCV2d inoculation. The present study further strengthens the use of the PCV2 vaccine as an important tool for prevention of PCVAD in pigs.
Disease caused by infection with porcine circovirus type 2 (PCV2), collectively known as porcine circovirus-associated disease (PCVAD), is one of the most important viral infectious diseases in pigs. To date, PCV2 has been classified into at least 8 genotypes, namely PCV2a, PCV2b, PCV2c, PCV2d, PCV2e, PCV2f, PCV2g, and PCV2h. Among these, PCV2a, PCV2b, and PCV2d are the predominant genotypes that have chronologically circulated and affected the global pig population. Application of the PCV2 vaccine is a key strategy in the prevention and control of PCV2 infection. However, to the best of our knowledge, little is known about the benefits of using the chimeric PCV2a-2b antigen-based vaccine in Thailand in experimental challenges with field isolates of PCV2d. The present study has demonstrated that the chimeric PCV1-2a-based vaccine and the chimeric PCV1-2a-2b-based vaccine are effective against Thai PCV2d inoculation. The present study further strengthens the use of the PCV2 vaccine as an important tool for prevention of PCVAD in pigs. The objective of this study was to evaluate the efficacy of two multivalent commercial porcine circovirus (PCV) vaccines against heterologous PCV2d challenges. A total of 24 crossbred male pigs aged 26 days selected from a specific pathogen-free herd were randomly divided into four groups (six pigs per group) and assigned as follows: negative control (unvaccinated/sham-challenge), vaccinated with chimeric PCV1-2a vaccine (PCV1-2a/PCV2d-challenge), vaccinated with chimeric PCV1-2a-2b vaccine (PCV1-2a-2b/PCV2d-challenge) and positive control (unvaccinated/PCV2d-challenge). At 21 days after vaccination, the pigs were intranasally and intramuscularly inoculated with either sham or field isolates of PCV2d (PCV2d/149/TH/2020). After being challenged, blood samples were obtained weekly and analyzed for levels of PCV2d viremia, neutralizing antibodies, and IgG against PCV2. At 30 days post-challenge (DPC), the pigs were euthanized and then subjected to pathological evaluations and molecular analysis. The results indicated that pigs in the PCV1-2a-2b/PCV2d-challenge and the PCV1-2a/PCV2d-challenge groups possessed significantly greater levels of PCV2d-neutralizing antibody titer when compared with the positive control group. Moreover, pigs in the PCV1-2a-2b/PCV2d-challenge group exhibited a lower degree of severity in terms of gross lesion scores and lower levels of PCV2 viremia when compared with the positive control group. This study demonstrated that vaccinating pigs with either the PCV1-2a or PCV1-2a-2b chimeric vaccines elicits a potent immune response against PCV2d infection and reduces viremia after PCV2d inoculation in pigs.
Simple SummaryDisease caused by infection with porcine circovirus type 2 (PCV2), collectively known as porcine circovirus-associated disease (PCVAD), is one of the most important viral infectious diseases in pigs. To date, PCV2 has been classified into at least 8 genotypes, namely PCV2a, PCV2b, PCV2c, PCV2d, PCV2e, PCV2f, PCV2g, and PCV2h. Among these, PCV2a, PCV2b, and PCV2d are the predominant genotypes that have chronologically circulated and affected the global pig population. Application of the PCV2 vaccine is a key strategy in the prevention and control of PCV2 infection. However, to the best of our knowledge, little is known about the benefits of using the chimeric PCV2a-2b antigen-based vaccine in Thailand in experimental challenges with field isolates of PCV2d. The present study has demonstrated that the chimeric PCV1-2a-based vaccine and the chimeric PCV1-2a-2b-based vaccine are effective against Thai PCV2d inoculation. The present study further strengthens the use of the PCV2 vaccine as an important tool for prevention of PCVAD in pigs. AbstractThe objective of this study was to evaluate the efficacy of two multivalent commercial porcine circovirus (PCV) vaccines against heterologous PCV2d challenges. A total of 24 crossbred male pigs aged 26 days selected from a specific pathogen-free herd were randomly divided into four groups (six pigs per group) and assigned as follows: negative control (unvaccinated/sham-challenge), vaccinated with chimeric PCV1-2a vaccine (PCV1-2a/PCV2d-challenge), vaccinated with chimeric PCV1-2a-2b vaccine (PCV1-2a-2b/PCV2d-challenge) and positive control (unvaccinated/PCV2d-challenge). At 21 days after vaccination, the pigs were intranasally and intramuscularly inoculated with either sham or field isolates of PCV2d (PCV2d/149/TH/2020). After being challenged, blood samples were obtained weekly and analyzed for levels of PCV2d viremia, neutralizing antibodies, and IgG against PCV2. At 30 days post-challenge (DPC), the pigs were euthanized and then subjected to pathological evaluations and molecular analysis. The results indicated that pigs in the PCV1-2a-2b/PCV2d-challenge and the PCV1-2a/PCV2d-challenge groups possessed significantly greater levels of PCV2d-neutralizing antibody titer when compared with the positive control group. Moreover, pigs in the PCV1-2a-2b/PCV2d-challenge group exhibited a lower degree of severity in terms of gross lesion scores and lower levels of PCV2 viremia when compared with the positive control group. This study demonstrated that vaccinating pigs with either the PCV1-2a or PCV1-2a-2b chimeric vaccines elicits a potent immune response against PCV2d infection and reduces viremia after PCV2d inoculation in pigs.
The objective of this study was to evaluate the efficacy of two multivalent commercial porcine circovirus (PCV) vaccines against heterologous PCV2d challenges. A total of 24 crossbred male pigs aged 26 days selected from a specific pathogen-free herd were randomly divided into four groups (six pigs per group) and assigned as follows: negative control (unvaccinated/sham-challenge), vaccinated with chimeric PCV1-2a vaccine (PCV1-2a/PCV2d-challenge), vaccinated with chimeric PCV1-2a-2b vaccine (PCV1-2a-2b/PCV2d-challenge) and positive control (unvaccinated/PCV2d-challenge). At 21 days after vaccination, the pigs were intranasally and intramuscularly inoculated with either sham or field isolates of PCV2d (PCV2d/149/TH/2020). After being challenged, blood samples were obtained weekly and analyzed for levels of PCV2d viremia, neutralizing antibodies, and IgG against PCV2. At 30 days post-challenge (DPC), the pigs were euthanized and then subjected to pathological evaluations and molecular analysis. The results indicated that pigs in the PCV1-2a-2b/PCV2d-challenge and the PCV1-2a/PCV2d-challenge groups possessed significantly greater levels of PCV2d-neutralizing antibody titer when compared with the positive control group. Moreover, pigs in the PCV1-2a-2b/PCV2d-challenge group exhibited a lower degree of severity in terms of gross lesion scores and lower levels of PCV2 viremia when compared with the positive control group. This study demonstrated that vaccinating pigs with either the PCV1-2a or PCV1-2a-2b chimeric vaccines elicits a potent immune response against PCV2d infection and reduces viremia after PCV2d inoculation in pigs.The objective of this study was to evaluate the efficacy of two multivalent commercial porcine circovirus (PCV) vaccines against heterologous PCV2d challenges. A total of 24 crossbred male pigs aged 26 days selected from a specific pathogen-free herd were randomly divided into four groups (six pigs per group) and assigned as follows: negative control (unvaccinated/sham-challenge), vaccinated with chimeric PCV1-2a vaccine (PCV1-2a/PCV2d-challenge), vaccinated with chimeric PCV1-2a-2b vaccine (PCV1-2a-2b/PCV2d-challenge) and positive control (unvaccinated/PCV2d-challenge). At 21 days after vaccination, the pigs were intranasally and intramuscularly inoculated with either sham or field isolates of PCV2d (PCV2d/149/TH/2020). After being challenged, blood samples were obtained weekly and analyzed for levels of PCV2d viremia, neutralizing antibodies, and IgG against PCV2. At 30 days post-challenge (DPC), the pigs were euthanized and then subjected to pathological evaluations and molecular analysis. The results indicated that pigs in the PCV1-2a-2b/PCV2d-challenge and the PCV1-2a/PCV2d-challenge groups possessed significantly greater levels of PCV2d-neutralizing antibody titer when compared with the positive control group. Moreover, pigs in the PCV1-2a-2b/PCV2d-challenge group exhibited a lower degree of severity in terms of gross lesion scores and lower levels of PCV2 viremia when compared with the positive control group. This study demonstrated that vaccinating pigs with either the PCV1-2a or PCV1-2a-2b chimeric vaccines elicits a potent immune response against PCV2d infection and reduces viremia after PCV2d inoculation in pigs.
Audience Academic
Author Photichai, Kornravee
Yamsakul, Panuwat
Sukmak, Manakorn
Pringproa, Kidsadagon
Thanawongnuwech, Roongroje
Sittisak, Tidaratt
Srivorakul, Saralee
Arunorat, Jirapat
Guntawang, Thunyamas
Wongchanapai, Pichanun
AuthorAffiliation 3 Department of Food Animal Clinic, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand
1 Department of Veterinary Biosciences and Veterinary Public Health, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand
5 Department of Pathology, Faculty of Veterinary Sciences, Chulalongkorn University, Bangkok 10330, Thailand
4 Center of Veterinary Diagnosis and Technology Transfer, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand
2 Swine Business Unit, Zoetis (Thailand) Limited, Bangkok 10500, Thailand
6 Department of Farm Resources and Production Medicine, Faculty of Veterinary Medicine, Kasetsart University, Nakorn Pathom 73140, Thailand
7 Center of Excellence in Elephant and Wildlife Research, Chiang Mai University, Chiang Mai 50100, Thailand
AuthorAffiliation_xml – name: 2 Swine Business Unit, Zoetis (Thailand) Limited, Bangkok 10500, Thailand
– name: 7 Center of Excellence in Elephant and Wildlife Research, Chiang Mai University, Chiang Mai 50100, Thailand
– name: 3 Department of Food Animal Clinic, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand
– name: 1 Department of Veterinary Biosciences and Veterinary Public Health, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand
– name: 5 Department of Pathology, Faculty of Veterinary Sciences, Chulalongkorn University, Bangkok 10330, Thailand
– name: 6 Department of Farm Resources and Production Medicine, Faculty of Veterinary Medicine, Kasetsart University, Nakorn Pathom 73140, Thailand
– name: 4 Center of Veterinary Diagnosis and Technology Transfer, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand
Author_xml – sequence: 1
  givenname: Pichanun
  surname: Wongchanapai
  fullname: Wongchanapai, Pichanun
– sequence: 2
  givenname: Panuwat
  surname: Yamsakul
  fullname: Yamsakul, Panuwat
– sequence: 3
  givenname: Jirapat
  surname: Arunorat
  fullname: Arunorat, Jirapat
– sequence: 4
  givenname: Thunyamas
  surname: Guntawang
  fullname: Guntawang, Thunyamas
– sequence: 5
  givenname: Tidaratt
  surname: Sittisak
  fullname: Sittisak, Tidaratt
– sequence: 6
  givenname: Saralee
  surname: Srivorakul
  fullname: Srivorakul, Saralee
– sequence: 7
  givenname: Kornravee
  surname: Photichai
  fullname: Photichai, Kornravee
– sequence: 8
  givenname: Roongroje
  orcidid: 0000-0002-8780-9819
  surname: Thanawongnuwech
  fullname: Thanawongnuwech, Roongroje
– sequence: 9
  givenname: Manakorn
  surname: Sukmak
  fullname: Sukmak, Manakorn
– sequence: 10
  givenname: Kidsadagon
  surname: Pringproa
  fullname: Pringproa, Kidsadagon
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36851384$$D View this record in MEDLINE/PubMed
BookMark eNqFks9rFDEcxQep2Fp79SgDXuphayaZ_LoIZVhtoWAP2mv4TuabacrMZE1mF_vfm7W17RZFckhI3vskebzXxd4UJiyKtxU5YUyTjxuck_UVIZQQRV4UB5QRsZBMVXtP1vvFUUo3hJCK1ZTL6lWxz4TiFVP1QbFuwriCCLPfYLl0zluwt2VwZXPtR4zelpchWj9h2fhow8bHdSqPL5urD-UV2O1BKqEHP6W5XP5cZceI0wxDeYYzxjCEPmRD1tMuI2EYcOoxvSleOhgSHt3Ph8X3z8tvzdni4uuX8-b0YmG5qucFdooL0hJKO8mQKmIrLYQTTIJG13WOuspZJdHVyjptSUUrLiV3rBaOdcAOi_M7bhfgxqzy4yDemgDe_N4IsTcQZ28HNKioEi1tWw2k5hJAE-QZqQHq1nKdWZ_uWKt1O2Jn8zcjDDvQ3ZPJX5s-bIzWXFPOMuD4HhDDjzWm2Yw-WRwGmDCHZBip881CkPq_UioVkYIKrbL0_TPpTVjHKaeaVVKLTGXkUdVD_qufXMhPtFuoOZWcUsGU2l578hdVHh2O3ubuOZ_3dwzvnmbyEMaffj0SbQwpRXQPkoqYbYfNboezoX5msH7O7QzbTP3wL9svpMj03A
CitedBy_id crossref_primary_10_1097_JS9_0000000000001198
crossref_primary_10_1016_j_tvjl_2024_106199
Cites_doi 10.1111/j.1939-1676.2009.0389.x
10.1186/s12985-021-01541-z
10.1016/S0166-0934(99)00043-9
10.1016/j.virusres.2016.11.015
10.1128/JVI.78.12.6297-6303.2004
10.1016/j.vaccine.2009.04.028
10.1177/104063879901100607
10.1016/j.vetimm.2010.03.025
10.1128/CVI.05027-11
10.3390/vaccines10091469
10.1016/j.tvjl.2010.03.023
10.1007/s13337-018-0476-y
10.1038/srep39458
10.1016/j.vaccine.2020.01.013
10.1016/j.vetmic.2017.08.006
10.3390/vetsci6030061
10.1016/j.vetmic.2019.03.002
10.3389/fmicb.2018.00455
10.1111/tbed.13446
10.1016/j.vetimm.2020.110034
10.1016/S0165-2427(03)00079-5
10.3390/ani12080953
10.1016/j.vaccine.2019.09.029
10.1111/j.1865-1682.2011.01288.x
10.1016/j.vaccine.2016.11.085
10.1016/j.vaccine.2021.08.013
ContentType Journal Article
Copyright COPYRIGHT 2023 MDPI AG
2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023 by the authors. 2023
Copyright_xml – notice: COPYRIGHT 2023 MDPI AG
– notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023 by the authors. 2023
DBID AAYXX
CITATION
NPM
8FE
8FH
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
HCIFZ
LK8
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
7S9
L.6
5PM
DOA
DOI 10.3390/vetsci10020080
DatabaseName CrossRef
PubMed
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
ProQuest Central Student
SciTech Premium Collection
ProQuest Biological Science Collection
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DOAJ (Directory of Open Access Journals)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Biological Science Collection
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
Biological Science Database
ProQuest SciTech Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Academic UKI Edition
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList

AGRICOLA

Publicly Available Content Database
MEDLINE - Academic
CrossRef
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Veterinary Medicine
EISSN 2306-7381
ExternalDocumentID oai_doaj_org_article_e8286b2bb9a0457aa90e59c09aa4bc59
PMC9959253
A752263884
36851384
10_3390_vetsci10020080
Genre Journal Article
GeographicLocations Thailand
United States--US
GeographicLocations_xml – name: Thailand
– name: United States--US
GrantInformation_xml – fundername: Zoetis (Thailand) Limited
– fundername: Center of Excellence in Elephant and Wildlife Research
– fundername: the Laboratory Animal Center
– fundername: Chiang Mai University, Thailand
– fundername: the National Research Council of Thailand (NRCT)
  grantid: 2022#N42650553
GroupedDBID 5VS
8FE
8FH
AADQD
AAFWJ
AAHBH
AAYXX
ADBBV
AFKRA
AFPKN
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BCNDV
BENPR
BHPHI
CCPQU
CITATION
ECGQY
EYRJQ
GROUPED_DOAJ
HCIFZ
HYE
IAO
ITC
KQ8
LK8
M7P
MODMG
M~E
OK1
OZF
PGMZT
PHGZM
PHGZT
PIMPY
PROAC
RPM
NPM
PQGLB
PMFND
ABUWG
AZQEC
DWQXO
GNUQQ
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
PUEGO
7X8
7S9
L.6
5PM
ID FETCH-LOGICAL-c584t-ed8560b022d73e280c1966f637a9efddf2f1fc87ef48cf9c01215775f346f3da3
IEDL.DBID DOA
ISSN 2306-7381
IngestDate Wed Aug 27 00:31:53 EDT 2025
Thu Aug 21 18:37:48 EDT 2025
Fri Jul 11 11:45:49 EDT 2025
Fri Jul 11 05:39:00 EDT 2025
Sat Aug 23 12:39:42 EDT 2025
Tue Jun 17 21:08:44 EDT 2025
Tue Jun 10 20:25:28 EDT 2025
Mon Jul 21 06:05:24 EDT 2025
Tue Jul 01 00:41:29 EDT 2025
Thu Apr 24 23:11:16 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords challenge
Porcine circovirus type 2
heterologous PCV2
chimeric vaccine
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c584t-ed8560b022d73e280c1966f637a9efddf2f1fc87ef48cf9c01215775f346f3da3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-8780-9819
OpenAccessLink https://doaj.org/article/e8286b2bb9a0457aa90e59c09aa4bc59
PMID 36851384
PQID 2779630430
PQPubID 2059540
ParticipantIDs doaj_primary_oai_doaj_org_article_e8286b2bb9a0457aa90e59c09aa4bc59
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9959253
proquest_miscellaneous_3040456604
proquest_miscellaneous_2780762698
proquest_journals_2779630430
gale_infotracmisc_A752263884
gale_infotracacademiconefile_A752263884
pubmed_primary_36851384
crossref_primary_10_3390_vetsci10020080
crossref_citationtrail_10_3390_vetsci10020080
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20230121
PublicationDateYYYYMMDD 2023-01-21
PublicationDate_xml – month: 1
  year: 2023
  text: 20230121
  day: 21
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Veterinary sciences
PublicationTitleAlternate Vet Sci
PublicationYear 2023
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Opriessnig (ref_14) 2020; 38
Zhang (ref_13) 2020; 67
Chianini (ref_20) 2003; 94
Gerber (ref_18) 2011; 188
Franzo (ref_4) 2016; 6
Thangthamniyom (ref_7) 2017; 208
Bandrick (ref_16) 2020; 223
ref_17
Link (ref_3) 2021; 18
Kwon (ref_5) 2017; 228
Fort (ref_8) 2009; 27
Seo (ref_12) 2011; 18
McNeilly (ref_26) 1999; 80
Kekarainen (ref_10) 2010; 136
Opriessnig (ref_11) 2017; 35
Gillespie (ref_1) 2009; 23
Huan (ref_22) 2018; 9
Park (ref_24) 2019; 231
ref_23
Baekbo (ref_2) 2012; 59
Hemann (ref_9) 2014; 78
Opriessnig (ref_15) 2019; 37
Taylor (ref_25) 2021; 39
Sorden (ref_27) 1999; 11
Henriques (ref_19) 2018; 29
Fenaux (ref_21) 2004; 78
ref_6
References_xml – volume: 23
  start-page: 1151
  year: 2009
  ident: ref_1
  article-title: Porcine circovirus type 2 and porcine circovirus-associated disease
  publication-title: J. Vet. Intern. Med.
  doi: 10.1111/j.1939-1676.2009.0389.x
– volume: 18
  start-page: 70
  year: 2021
  ident: ref_3
  article-title: Discriminating the eight genotypes of the porcine circovirus type 2 with TaqMan-based real-time PCR
  publication-title: Virol. J.
  doi: 10.1186/s12985-021-01541-z
– volume: 80
  start-page: 123
  year: 1999
  ident: ref_26
  article-title: A comparison of in situ hybridization and immunohistochemistry for the detection of a new porcine circovirus in formalin-fixed tissues from pigs with post-weaning multisystemic wasting syndrome (PMWS)
  publication-title: J. Virol. Methods
  doi: 10.1016/S0166-0934(99)00043-9
– volume: 228
  start-page: 24
  year: 2017
  ident: ref_5
  article-title: Genotypic diversity of porcine circovirus type 2 (PCV2) and genotype shift to PCV2d in Korean pig population
  publication-title: Virus Res.
  doi: 10.1016/j.virusres.2016.11.015
– volume: 78
  start-page: 6297
  year: 2004
  ident: ref_21
  article-title: A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs
  publication-title: J. Virol.
  doi: 10.1128/JVI.78.12.6297-6303.2004
– volume: 27
  start-page: 4031
  year: 2009
  ident: ref_8
  article-title: One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2009.04.028
– volume: 11
  start-page: 528
  year: 1999
  ident: ref_27
  article-title: Development of a polyclonal-antibody-based immunohistochemical method for the detection of type 2 porcine circovirus in formalin-fixed, paraffin-embedded tissue
  publication-title: J. Vet. Diagn. Investig.
  doi: 10.1177/104063879901100607
– volume: 136
  start-page: 185
  year: 2010
  ident: ref_10
  article-title: Immune responses and vaccine-induced immunity against Porcine circovirus type 2
  publication-title: Vet. Immunol. Immunopathol.
  doi: 10.1016/j.vetimm.2010.03.025
– volume: 78
  start-page: 8
  year: 2014
  ident: ref_9
  article-title: A live-attenuated and an inactivated chimeric porcine circovirus (PCV)1-2 vaccine are both effective at inducing a humoral immune response and reducing PCV2 viremia and intrauterine infection in female swine of breeding age
  publication-title: Can. J. Vet. Res.
– volume: 18
  start-page: 1091
  year: 2011
  ident: ref_12
  article-title: Effects of an inactivated porcine circovirus type 2 (PCV2) vaccine on PCV2 virus shedding in semen from experimentally infected boars
  publication-title: Clin. Vaccine Immunol.
  doi: 10.1128/CVI.05027-11
– ident: ref_23
  doi: 10.3390/vaccines10091469
– volume: 188
  start-page: 240
  year: 2011
  ident: ref_18
  article-title: Serum antibodies and shedding of infectious porcine circovirus 2 into colostrum and milk of vaccinated and unvaccinated naturally infected sows
  publication-title: Vet. J.
  doi: 10.1016/j.tvjl.2010.03.023
– volume: 29
  start-page: 355
  year: 2018
  ident: ref_19
  article-title: Development and validation of a real-time PCR for the detection and quantification of porcine circovirus type 2
  publication-title: Virusdisease
  doi: 10.1007/s13337-018-0476-y
– volume: 6
  start-page: 39458
  year: 2016
  ident: ref_4
  article-title: Porcine circovirus type 2 (PCV2) evolution before and after the vaccination introduction: A large scale epidemiological study
  publication-title: Sci. Rep.
  doi: 10.1038/srep39458
– volume: 38
  start-page: 1975
  year: 2020
  ident: ref_14
  article-title: Porcine circovirus type 2a or 2b based experimental vaccines provide protection against PCV2d/porcine parvovirus 2 co-challenge
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2020.01.013
– volume: 208
  start-page: 239
  year: 2017
  ident: ref_7
  article-title: Genetic diversity of porcine circovirus type 2 (PCV2) in Thailand during 2009–2015
  publication-title: Vet. Microbiol.
  doi: 10.1016/j.vetmic.2017.08.006
– ident: ref_17
  doi: 10.3390/vetsci6030061
– volume: 231
  start-page: 87
  year: 2019
  ident: ref_24
  article-title: Evaluation of a porcine circovirus type 2a (PCV2a) vaccine efficacy against experimental PCV2a, PCV2b, and PCV2d challenge
  publication-title: Vet. Microbiol.
  doi: 10.1016/j.vetmic.2019.03.002
– volume: 9
  start-page: 455
  year: 2018
  ident: ref_22
  article-title: Evaluation of the Efficacy and Cross-Protective Immunity of Live-Attenuated Chimeric PCV1-2b Vaccine Against PCV2b and PCV2d Subtype Challenge in Pigs
  publication-title: Front. Microbiol.
  doi: 10.3389/fmicb.2018.00455
– volume: 67
  start-page: 1057
  year: 2020
  ident: ref_13
  article-title: Novel circovirus species identified in farmed pigs designated as Porcine circovirus 4, Hunan province, China
  publication-title: Transbound. Emerg. Dis.
  doi: 10.1111/tbed.13446
– volume: 223
  start-page: 110034
  year: 2020
  ident: ref_16
  article-title: T cell epitope content comparison (EpiCC) analysis demonstrates a bivalent PCV2 vaccine has greater T cell epitope overlap with field strains than monovalent PCV2 vaccines
  publication-title: Vet. Immunol. Immunopathol.
  doi: 10.1016/j.vetimm.2020.110034
– volume: 94
  start-page: 63
  year: 2003
  ident: ref_20
  article-title: Immunohistochemical characterisation of PCV2 associate lesions in lymphoid and non-lymphoid tissues of pigs with natural postweaning multisystemic wasting syndrome (PMWS)
  publication-title: Vet. Immunol. Immunopathol.
  doi: 10.1016/S0165-2427(03)00079-5
– ident: ref_6
  doi: 10.3390/ani12080953
– volume: 37
  start-page: 6688
  year: 2019
  ident: ref_15
  article-title: A Porcine circovirus type 2b (PCV2b)-based experimental vaccine is effective in the PCV2b-Mycoplasma hyopneumoniae coinfection pig model
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2019.09.029
– volume: 59
  start-page: 60
  year: 2012
  ident: ref_2
  article-title: Porcine circovirus diseases: A review of PMWS
  publication-title: Transbound Emerg. Dis.
  doi: 10.1111/j.1865-1682.2011.01288.x
– volume: 35
  start-page: 248
  year: 2017
  ident: ref_11
  article-title: A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naive pigs under experimental conditions
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2016.11.085
– volume: 39
  start-page: 5615
  year: 2021
  ident: ref_25
  article-title: Cellular and humoral immunity following vaccination with two different PCV2 vaccines (containing PCV2a or PCV2a/PCV2b) and challenge with virulent PCV2d
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2021.08.013
SSID ssj0001342571
Score 2.229807
Snippet The objective of this study was to evaluate the efficacy of two multivalent commercial porcine circovirus (PCV) vaccines against heterologous PCV2d challenges....
Disease caused by infection with porcine circovirus type 2 (PCV2), collectively known as porcine circovirus-associated disease (PCVAD), is one of the most...
Simple SummaryDisease caused by infection with porcine circovirus type 2 (PCV2), collectively known as porcine circovirus-associated disease (PCVAD), is one of...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 80
SubjectTerms Analysis
Antibodies
Antigens
blood
challenge
chimeric vaccine
Genotypes
herds
heterologous PCV2
Histopathology
Hogs
Immune response
Immunization
Immunoglobulin G
Immunology
Infectious diseases
Inoculation
Laboratory animals
Lungs
Lymphatic system
males
Pathogens
Porcine circovirus
Porcine circovirus type 2
Specific pathogen free
specific pathogen-free animals
Swine
Vaccination
Vaccines
Variance analysis
Viremia
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBbt5tJLadPXtmlRodD2YGJbtiWdSmI2LIWGpTRLbkbWIzEEO7V3A_n3mbG1D1PSqzW2JM9T0ugbQr6UkYFVgxGBEbEM8PJjUGacBc5IJyOnjTZ9gux5Nr9Ifl6ml37DrfNplRub2Btq02jcIz-OOQdZQYSqH7d_A6wahaervoTGU3IAJliICTk4nZ0vfu92WRjKZDSgNTJY3x_f2RX4FgQeDXssyD1v1IP2_2ua93zTOG9yzxGdvSDPfQRJTwaWvyRPbH1IDpeY1tLfraW__HH5K7LOd9jedIZgEUrf08bR_LrqT2roommRlOZVq5u7ql139NsiX36nS6WxoaPqSlUQQtLZXikAOsfe0Gw28ALQxwY-6auydK_JxdnsTz4PfJ2FQEP4sQqsERD3lODNDWc2FqEGtcxcxriS1hnjYgdcE9y6RGgnNcLApZynjiWZY0axN2RSN7V9R2iWglC4UpSZsIlIhEq1AQsqM6ciCDX0lASb_11oD0KOtTBuCliMIH-KMX-m5OuW_naA33iU8hTZt6VC2Oz-QdNeFV4LC4uX5su4LKWCUJYrJUObwoSkUkmpUwndIfMLVG4YFjBluKMAk0OYrOKEY7jKhEim5GhECUqpx80b8Sm8UeiKnQhPyedtM76JiW61BZYBjQjBP2VSPE4Dn8BAPAuhm7eDRG6njfUEIoYD4CNZHf2XcUtdXfew4og8F6fs_f-H_oE8iyHOw12oODoik1W7th8hLluVn7zyPQB8xjvN
  priority: 102
  providerName: ProQuest
Title Comparative Efficacy of Chimeric Porcine Circovirus (PCV) Vaccines against Experimental Heterologous PCV2d Challenges
URI https://www.ncbi.nlm.nih.gov/pubmed/36851384
https://www.proquest.com/docview/2779630430
https://www.proquest.com/docview/2780762698
https://www.proquest.com/docview/3040456604
https://pubmed.ncbi.nlm.nih.gov/PMC9959253
https://doaj.org/article/e8286b2bb9a0457aa90e59c09aa4bc59
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Na9VAEF-kXryI1q-nbVlBUA-hSTbZj2MbXnkIlofYR29hP21AEnkfBf_7zmzSZ4IUL16zk-xmZnZmNpn5DSEfTObg1OBk4mSuEix-TAwXLAlOBZUF66yLCbKXfHFVfLkur0etvjAnrIcH7hl36rHO2eTGKA3Rh9Bapb5UNlVaF8aWsXQPfN7oMBW_rjDUxaxHaWRwrj-99VvwKQg4mkYMyJEXimD9f5vkkU-a5kuOHNDFM_J0iBzpWb_i5-SRbw_J4QrTWWJNLf06_CZ_QXbVH0xvOkeQCG1_0y7Q6qaJf2joslsjKa2ate1um_VuQz8tq9VnutIWBzZU_9ANhI50PmoBQBc4G5rLDm4A-tzBI4duLJuX5Opi_r1aJEN_hcRC2LFNvJMQ7xjw4k4wn8vUwnbkgTOhlQ_OhTyAtKTwoZA2AM8RiUKIMrCCB-Y0e0UO2q71bwjlJShDMNJw6QtZSF1aB5ZT8aAzCDHsjCT3_K7tAD6OPTB-1nAIQfnUU_nMyMc9_a8eduNBynMU354K4bLjBVCielCi-l9KBNOh8Gvc1LAsEEpfmwAvh_BY9ZnAMJVJWczI0YQSNqOdDt-rTz0Yg02dCwFmDsHVZuT9fhjvxAS31oPIgEam4Je4kg_TwCMwAOcpTPO618j9a2MfgYzhAsREVyd8mY60zU2EE0fEubxkb_8HI9-RJzlEgfiNKs-OyMF2vfPHELVtzQl5fD6_XH47iRv1Dio6RPs
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbK9gAXBOW1UMBIIOAQNbETxz4g1C5bbWm7WqF21Vvq-NGuhDZlH0X9U_xGZpLsI0Ll1ms88WvGM2N7_A0h7_PIwq7BysBKpgJ8_BjkIuWBt8qryBtrbBkg2xe90_j7WXK2Qf4s3sJgWOVCJ5aK2hYGz8h3WJqCrCBC1derXwFmjcLb1UUKjUosDt3Nb9iyTb8cfAP-fmBsv3vS6QV1VoHAgLGdBc5KsPI52C6bcsdkaEAIhRc81cp5az3z0EeZOh9L45VB0LMkTRPPY-G51RzqvUc2Yy5C1iKbe93-4MfqVIfjGogqdEjOVbhz7WZgyxDoNCyxJ9esX5kk4F9TsGYLm3Gaa4Zv_xF5WHusdLcSscdkw423yNYQw2jKt7z0uL6ef0LmnRWWOO0iOIU2N7TwtHM5Km-G6KCYICntjCamuB5N5lP6adAZfqZDbbBgSvWFHoHLSrtrqQdoD1tDNV3AD0DPLFRZZ4GZPiWnd8KBZ6Q1LsbuBaEiASH0ucyFdLGMpU6MBY2thNcRuDamTYLFfGemBj3H3Bs_M9j8IH-yJn_a5OOS_qqC-7iVcg_Zt6RCmO7yQzG5yOpVnzl8pJ-zPFcaXOdUaxW6BAaktI5zkyhoDpmfoTKBbgFTqjcRMDiE5cp2U3SPuZRxm2w3KEEJmGbxQnyyWglNs9WSaZN3y2L8EwPrxg5YBjQyBHsolLydBqpAx1-E0MzzSiKXw8b8BRHHDqQNWW3MS7NkPLosYcwR6Y4l_OX_u_6W3O-dHB9lRwf9w1fkAQMfE0_AWLRNWrPJ3L0Gn3CWv6kXIiXnd732_wII0HkG
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVkJcEJTXQgEjgYBDtImdxPYBoXa7qy2F1QrRqrfU8aNdCW3KPor61_h1zCTZR4TKrdd44teMZ8b2-BtC3uaRhV2DlYGVTAX4-DHIU8EDb5VXkTfW2DJAdpgOjuMvp8npFvmzfAuDYZVLnVgqalsYPCPvMCFAVhChquPrsIjRQf_z5a8AM0jhTesynUYlIkfu-jds32afDg-A1-8Y6_d-dAdBnWEgMGB454GzEix-DnbMCu6YDA0IZOpTLrRy3lrPPPRXCudjabwyCICWCJF4HqeeW82h3jtkW-CuqEW293vD0ff1CQ_H9RBVSJGcq7Bz5eZg1xD0NCxxKDcsYZkw4F-zsGEXmzGbG0aw_4Dcr71XuleJ20Oy5SY7ZOcEQ2rKd730W31V_4gsumtccdpDoAptrmnhafdiXN4S0VExRVLaHU9NcTWeLmb0w6h78pGeaIMFM6rP9RjcV9rbSENAB9gaquwCfgB6ZqHKOiPM7DE5vhUOPCGtSTFxzwhNExBIn8s8lS6WsdSJsaC9Vep1BG6OaZNgOd-ZqQHQMQ_Hzww2QsifrMmfNnm_or-soD9upNxH9q2oELK7_FBMz7NaA2QOH-znLM-VBjdaaK1Cl8CAlNZxbhIFzSHzM1Qs0C1gSvU-AgaHEF3ZnkBXmUsZt8lugxIUgmkWL8UnqxXSLFsvnzZ5syrGPzHIbuKAZUAjQ7CNqZI300AVuAlIQ2jmaSWRq2FjLoOIYwdEQ1Yb89IsmYwvSkhzRL1jCX_-_66_JndhzWdfD4dHL8g9Bu4mHoaxaJe05tOFewnu4Tx_Va9DSs5ue-n_BXS0fTs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparative+Efficacy+of+Chimeric+Porcine+Circovirus+Vaccines+against+Experimental+Heterologous+PCV2d+Challenges&rft.jtitle=Veterinary+sciences&rft.au=Wongchanapai%2C+Pichanun&rft.au=Yamsakul%2C+Panuwat&rft.au=Arunorat%2C+Jirapat&rft.au=Guntawang%2C+Thunyamas&rft.date=2023-01-21&rft.pub=MDPI+AG&rft.issn=2306-7381&rft.eissn=2306-7381&rft.volume=10&rft.issue=2&rft_id=info:doi/10.3390%2Fvetsci10020080&rft.externalDocID=A752263884
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2306-7381&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2306-7381&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2306-7381&client=summon